Literature DB >> 33628271

Combined Treatment of Adipose Derived-Mesenchymal Stem Cells and Pregabalin Is Superior to Monotherapy for the Treatment of Neuropathic Pain in Rats.

Shimaa Mohammad Yousof1,2, Doaa Attia ElSayed1, Amani A El-Baz1, Hanaa S Sallam1,3, Faten Abbas1.   

Abstract

AIMS: Neuropathic pain following nerve injury does not respond well to most available pharmacological remedies. We aimed to compare the outcome of the addition of adipose-derived mesenchymal stem cells (ADMSCs) to pregabalin for neuropathic pain treatment.
METHODS: Adult female albino rats (n = 100) were randomized to receive traumatic sciatic nerve injury or sham. Animals were then randomized to ADMSC treatment with or without pregabalin. We conducted a battery of neurobehavioral and electrophysiological to assess neuropathic pain. Following sacrifice, we evaluated the histological changes and gene expression of brain-derived neurotrophic factor (BDNF) in the sciatic nerve. Serum and sciatic nerve tissue pro- and inflammatory cytokine levels were also assessed.
RESULTS: (1) All treatments significantly improved thermal withdrawal latency, sciatic nerve conduction velocity, and proinflammatory cytokine levels in injured animals, with no significant effect of the combined treatments compared to pregabalin monotherapy (p < 0.05 each). (2) Combined treatment significantly improved medial gastrocnemius electromyographic amplitude and sciatic function index compared to pregabalin monotherapy (p < 0.05 each). (3) Combined treatment significantly increased the BDNF expression, decreased anti-inflammatory cytokine (p < 0.05 each), and restored the structural nerve damage, compared to pregabalin monotherapy.
CONCLUSIONS: Combined treatment is associated with greater improvement of the sciatic nerve structure and function. Further studies are warranted to study the mechanism of action of the combined treatment to improve neuropathic pain.
Copyright © 2021 Shimaa Mohammad Yousof et al.

Entities:  

Year:  2021        PMID: 33628271      PMCID: PMC7899775          DOI: 10.1155/2021/8847110

Source DB:  PubMed          Journal:  Stem Cells Int            Impact factor:   5.443


  37 in total

1.  Pharmacotherapy of neuropathic pain: time to rewrite the rulebook?

Authors:  Nanna B Finnerup; Nadine Attal
Journal:  Pain Manag       Date:  2015-12-17

Review 2.  Uncovering the secretes of mesenchymal stem cells.

Authors:  Jessie R Lavoie; Michael Rosu-Myles
Journal:  Biochimie       Date:  2013-06-28       Impact factor: 4.079

3.  Sex differences in neuropathic pain intensity in diabetes.

Authors:  Alon Abraham; Carolina Barnett; Hans D Katzberg; Leif E Lovblom; Bruce A Perkins; Vera Bril
Journal:  J Neurol Sci       Date:  2018-03-06       Impact factor: 3.181

4.  Neurotropin attenuates local inflammatory response and inhibits demyelination induced by chronic constriction injury of the mouse sciatic nerve.

Authors:  Shunsuke Nishimoto; Kiyoshi Okada; Hiroyuki Tanaka; Michio Okamoto; Hiroki Fujisawa; Tomoyuki Okada; Mitsuru Naiki; Tsuyoshi Murase; Hideki Yoshikawa
Journal:  Biologicals       Date:  2016-05-24       Impact factor: 1.856

5.  Pregabalin does not impact peripheral nerve regeneration after crush injury.

Authors:  Elizabeth L Whitlock; Arash Moradzadeh; Daniel A Hunter; Susan E Mackinnon
Journal:  J Reconstr Microsurg       Date:  2007-07       Impact factor: 2.873

6.  Duloxetine and pregabalin: high-dose monotherapy or their combination? The "COMBO-DN study"--a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain.

Authors:  Solomon Tesfaye; Stefan Wilhelm; Alberto Lledo; Alexander Schacht; Thomas Tölle; Didier Bouhassira; Giorgio Cruccu; Vladimir Skljarevski; Rainer Freynhagen
Journal:  Pain       Date:  2013-05-31       Impact factor: 6.961

7.  The purinergic antagonist PPADS reduces pain related behaviours and interleukin-1 beta, interleukin-6, iNOS and nNOS overproduction in central and peripheral nervous system after peripheral neuropathy in mice.

Authors:  Cataldo Martucci; Anna Elisa Trovato; Barbara Costa; Elisa Borsani; Silvia Franchi; Valerio Magnaghi; Alberto E Panerai; Luigi F Rodella; Anna Elisa Valsecchi; Paola Sacerdote; Mariapia Colleoni
Journal:  Pain       Date:  2007-09-27       Impact factor: 6.961

8.  Adipose-Derived Stem Cells Promote Peripheral Nerve Regeneration In Vivo without Differentiation into Schwann-Like Lineage.

Authors:  Yoshihiro Sowa; Tsunao Kishida; Tetsuya Imura; Toshiaki Numajiri; Kenichi Nishino; Yasuhiko Tabata; Osam Mazda
Journal:  Plast Reconstr Surg       Date:  2016-02       Impact factor: 4.730

9.  Transplantation of bone marrow-derived mesenchymal stem cells improves diabetic polyneuropathy in rats.

Authors:  Taiga Shibata; Keiko Naruse; Hideki Kamiya; Mika Kozakae; Masaki Kondo; Yutaka Yasuda; Nobuhisa Nakamura; Kimiko Ota; Takahiro Tosaki; Takashi Matsuki; Eitaro Nakashima; Yoji Hamada; Yutaka Oiso; Jiro Nakamura
Journal:  Diabetes       Date:  2008-08-26       Impact factor: 9.461

10.  Intravenous administration of adipose tissue-derived stem cells enhances nerve healing and promotes BDNF expression via the TrkB signaling in a rat stroke model.

Authors:  Xin Li; Wei Zheng; Hongying Bai; Jin Wang; Ruili Wei; Hongtao Wen; Hanbing Ning
Journal:  Neuropsychiatr Dis Treat       Date:  2016-06-02       Impact factor: 2.570

View more
  1 in total

Review 1.  Why Use Adipose-Derived Mesenchymal Stem Cells in Tendinopathic Patients: A Systematic Review.

Authors:  Annalisa Itro; Maria Consiglia Trotta; Roberta Miranda; Marco Paoletta; Annalisa De Cicco; Caterina Claudia Lepre; Umberto Tarantino; Michele D'Amico; Giuseppe Toro; Alfredo Schiavone Panni
Journal:  Pharmaceutics       Date:  2022-05-27       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.